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cense.Abstract Aim of the work: To identify the association of Y chromosome microchimerism with
systemic lupus erythematosus (SLE) and investigate its relation to pregnancy history, clinical and
laboratory variables.
Patients and methods: The presence of Y chromosome microchimerism was screened in 90
females including 35 women with renal lupus, 25 patients with cutaneous lupus and 30 healthy con-
trol females using real time polymerase chain reaction. Demographic parameters, reproductive his-
tory, clinical and laboratory data were recorded.
Results: The percentage of Y chromosome microchimerism was signiﬁcantly higher in SLE
patients compared to healthy women and in females with renal lupus versus those with cutaneous
lupus. Among patients with renal lupus, Y chromosome microchimerism was strongly associated
with disease activity and damage indices as well as with number of pregnancies, while thisustafa Mokhtar Street, From
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28 O. Abdulaziez et al.association was absent regarding number of pregnancies in cutaneous lupus females. A signiﬁcant
increase in disease activity and severity scores was detected in microchimeric renal lupus females
when compared to microchimeric cutaneous lupus patients. Healthy control and cutaneous lupus
women with microchimerism experienced signiﬁcant decrease in number of pregnancies and abor-
tions against microchimeric renal lupus group.
Conclusions: These results may provide a preliminary suggestion that Y chromosome micro-
chimerism could have a pathogenic role in SLE and it may be related to inﬂammation, the extent
of disease damage and reproductive history. Further studies are needed among SLE patients with
different clinical presentations, as fetal microchimerism is a promising ﬁeld of investigation which
may lead to novel strategies in treatment.
 2011 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
The term microchimerism indicates the coexistence, in the
same organism, of two cellular populations derived from two
different individuals. It takes place as a consequence of the
transfer of a low number of cells from one individual to an-
other and can occur in cases of pregnancy, organ transplanta-
tion and blood transfusion. Indeed, studies have shown that
fetal cells are transferred into the maternal circulation during
pregnancy. This phenomenon is called fetal cell microchimer-
ism and is characterized by the long term persistence of fetal
microchimeric cells in the maternal organs and in the circula-
tion without any apparent rejection [1].
It is likely that the consequences of persistent fetal micro-
chimerism depend on the constellation of factors including the
immunogenetic relationships between mother and fetus. Fetal
microchimerism appears to play a role in perturbation of mater-
nal immunity that may contribute to autoimmune diseases [2].
Increased recognition of fetal cells in the maternal circulation
has created interest in diseases associated with pregnancy. For
example, studies have implicated fetal cells in the development
of preeclampsia [3] and in the pathogenesis of scleroderma [4].
It is also possible that systemic lupus erythematosus (SLE)
may be related to fetomaternal transfusion. This is suggested
by the strong female predilection for the disease, the presence
of preeclampsia like syndrome with associated histological fea-
tures of the placenta and the clinical deterioration in the condi-
tion of some patients with SLE during pregnancy [5].
Thus fetomaternal cell trafﬁcking provides a potential
explanation for the increased prevalence of autoimmune disor-
ders in women following the childbearing period [6].
Despite that, studies on fetal cell microchimerism in auto-
immune diseases can be divided into two groups: those that
suggest an increase of fetal microchimeric cells in patients with
autoimmune diseases compared with healthy individuals [7,8]
and those that document the lack of a signiﬁcant difference be-
tween patients and healthy individuals [9,10].
The relative scarcity of fetal cells in maternal circulation
makes their identiﬁcation and characterization a challenge.
Most commonly, identiﬁcation of microchimeric fetal cells
has used a surrogate marker which is the cells that contain
male DNA, and in a female host which implies that these cells
have originated from a male fetus [11].
Our goal was to identify the association of Y chromosome
fetal microchimerism with systemic lupus erythematosus andinvestigate its relation to pregnancy history, clinical and labo-
ratory variables.
2. Patients and methods
2.1. Study participants
A total of 90 women were studied including: 30 healthy control
females with a mean age 28.4 ± 5.3 years and 60 patients with
SLE (their mean age was 36.6 ± 9.7 years) which consisted of
35 women with renal lupus and 25 patients with cutaneous lu-
pus (malar rash, discoid or subacute cutaneous lesions). All
women gave an informed consent before participation in the
study.
All SLE patients who were involved in this study were diag-
nosed according to the 1982 revised criteria of the American
College of Rheumatology for the diagnosis of SLE [12].
They were attending the Rheumatology and Rehabilitation,
Internal Medicine (Rheumatology and Nephrology) outpa-
tient clinics at Ain Shams University Hospitals in Cairo from
February 2009 till January 2011. Patients were diagnosed as
having renal lupus by renal biopsies according to the World
Health Organization Classiﬁcation System from the Interna-
tional Society of Nephrology/Renal Pathology [13] which were
previously performed during the disease course before their
enrollment in the study and their results were present in the pa-
tients’ medical records in addition to laboratory data including
serum creatinine >1.4 mg/dl or persistent proteinurea >0.5g/
day. Manifestations of renal disease were not detected in any
one of the patients with cutaneous lupus.
The overall disease activity was scored using the Systemic
Lupus Erythematosus Disease Activity Index (SLEDAI) [14],
patients were considered to have active disease if SLEDAI
was >4. The SLE cumulative organ damage was assessed
using the Systemic Lupus International Collaborating Clinics
(SLICC) damage index [15].
A detailed pregnancy history was taken from patients and
healthy control females including: number of pregnancies,
age at ﬁrst pregnancy, the outcome of pregnancies whether
sons, daughters or abortions and the age of oldest sons. All fe-
males were married and had a history of at least one pregnancy
before disease onset (regarding those who had been pregnant).
None of the patients or healthy control women gave a history
of organ transplantation, blood transfusion or was pregnant at
the time of study.
Figure 1 Comparison between systemic lupus erythematosus
patients and healthy control group regarding percentage of Y
chromosome microchimerism.
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Standard validated techniques were used for the laboratory
analyses. Indirect immunoﬂuorescence was used to detect anti-
nuclear (ANA) and anti-double stranded DNA (anti-dsDNA)
antibodies. Serum creatinine level was measured by Synchron
Cx-7 and 24 h urine was collected and evaluated using micro-
protein Eliech for the detection of proteinuria (>0.5 g/day).
The presence of anticardiolipin antibodies was tested (Stago;
Asnieres, France).
Genomic DNA was extracted from peripheral blood using
DNA blood puriﬁcation kit by arrow automated nucleic acid
extraction and puriﬁcation system (Nor Diag, Oslo, Norway)
according to the manufacturer’s instructions. Sex-determining
region Y (SRY) primers sequences used in the study were for-
ward primer, 5-GAA CGC CTT CAT TGT GTG GTC-3;
reverse primer, 5-TGG CTA GTA GTC TCT GTG CCT
CCT-3. Polymerase chain reaction (PCR) ampliﬁcation was
done by using SLAN AdvanSure real time PCR system (LG
Life Science, Seoul, Korea). Real-time PCR reactions were
done using SYBR green technology and were set up in a reac-
tion volume of 20 ll using Titan HotTaq EvaGreen PCR Mix
(BioAtlas, Tartu, Estonia). Each reaction contained 10 ll Ti-
tan HotTaq 2X EvaGreen mix, 250 nM of each primer and
3 ll extracted DNA. Each run was done by adding control po-
sitive (male DNA sample) and negative control (DNAse/
RNAse free water). The ampliﬁcation conditions consisted of
an initial incubation at 95 C for 15 min, followed by 40 cycles
of 95 C for 15 s and 55 C for 1 min [7].
Statistical analysis: Data were collected and analyzed using
SPSS V10 and the following was calculated: mean and stan-
dard deviation for continuous variables and frequency and
percentage for categorical variables. Independent sample Stu-
dent’s t test was used for comparison between two groups
regarding continuous variables. Chi square test was used for
comparison between two groups regarding categorical vari-
ables. Results were considered to be signiﬁcant if p< 0.05,
highly signiﬁcant if p< 0.001 and not signiﬁcant if p< 0.05.Figure 2 The percentage of Y chromosome microchimerism in
renal and cutaneous lupus females.3. Results
Microchimerism has been identiﬁed in 33/60 (55%) of SLE pa-
tients and 8/30 of healthy controls (26.7%), this difference had
reached statistical signiﬁcance v2 = 6.4, p< 0.05 (Fig. 1). The
same results were obtained for renal lupus females who expe-
rienced signiﬁcant increase in frequency of microchimerism
among 25/35 of patients (71.4%) in comparison to the cutane-
ous lupus group as it was detected in 8/25 of patients (32%),
v2 = 9.1, p< 0.05 (Fig. 2).
3.1. Microchimerism and demographic, clinical, laboratory
parameters
On screening patients with renal lupus, Y chromosome micro-
chimerism showed strong relation with disease activity and
damage indices (p= 0.000). The demographic, clinical and lab-
oratory data of the renal lupus group are given in Table 1. Using
Chi square test, no signiﬁcant association could be detected be-
tween Y chromosome microchimerism and different classes of
renal biopsy specimens, v2 = 5.0, p= 0.28. On the other hand,
the association between microchimerism and SLICC damageindex among women with cutaneous lupus (p= 0.02) was not
strong as that in the microchimeric renal group. Table 2 shows
the demographic, clinical and laboratory variables of cutaneous
lupus patients. Anticardiolipin antibodies were not signiﬁcantly
associated with the presence of microchimerism in both renal
and cutaneous lupus females, v2 = 2.3, p= 0.12 and
v2 = 0.18, p= 0.66, respectively.
The microchimeric renal lupus patients were characterized
by signiﬁcant increase in age, age at disease diagnosis, disease
duration, t= 6.6, 5.6, 6.2 (p< 0.001), respectively, more ac-
tive and severe disease (Table 3) when compared to the micro-
chimeric cutaneous lupus group.
3.2. Microchimerism and reproductive history
History of healthy control subjects revealed that two females
had at least one live birth son, four women reported at least
one abortion and 15 females had daughters while nine women
Table 1 Demographic parameters, pregnancy history, clinical and laboratory data of renal lupus females.
Variables Microchimerism present (n= 25) Microchimerism absent (n= 10) p Value
Age (years) 46.0 ± 4.5 29.1 ± 3.6 0.000*
Age at 1st pregnancy (years) 27.3 ± 2.8 21.5 ± 1.7 0.000*
Number of pregnancies 3.8 ± 1.1 1.3 ± 1.1 0.000*
Age at disease diagnosis (years) 34.21 ± 2.7 25.4 ± 2.7 0.000*
Disease duration (years) 11.8 ± 2.5 3.7 ± 1.6 0.000*
SLEDAI 15.9 ± 2.8 6.9 ± 1.5 0.000*
SLICC damage index 6.1 ± 0.86 3.5 ± 0.87 0.000*
Serum creatinine (mg/dl) 2.5 ± 0.26 2.2 ± 0.45 0.013**
Proteinuria positive/total (%) 24/25(96%) 6/10 (60%) 0.006**
ANA positive/total (%) 25/25 (100%) 10/10 (100%) NA
Antids DNA antibodies positive/total (%) 25/25 (100%) 10/10 (100%) NA
Anticardiolipin antibodies positive/total (%) 8/25 (32%) 6/10 (60%) 0.127
SLEDAI: Systemic Lupus Erythematosus Disease Activity Index, SLICC: Systemic Lupus International Collaborating Clinics, ANA: anti-
nuclear antibodies, Anti-dsDNA: anti-double stranded DNA, n: number, NA: not applicable.
* Highly signiﬁcant (p< 0.001).
** Signiﬁcant (p< 0.05).
Table 2 Demographic data, pregnancy history, clinical and laboratory characteristics of cutaneous lupus women.
Variables Microchimerism present (n= 8) Microchimerism absent (n= 17) p Value
Age (years) 32.6 ± 6.1 29.2 ± 7.5 0.284
Age at 1st pregnancy (years) 23.7 ± 3.3 23.3 ± 3.3 0.825
Number of pregnancies 1.0 ± 0.0 0.88 ± 1.1 0.770
Age at disease diagnosis (years) 27.1 ± 3.9 24.9 ± 4.5 0.255
Disease duration (years) 5.5 ± 2.3 4.3 ± 3.1 0.367
SLEDAI 3.6 ± 0.37 2.4 ± 0.43 0.000*
SLICC damage index 1.9 ± 0.73 1.4 ± 0.33 0.025**
Serum creatinine (mg/dl) 0.86 ± 0.16 0.82 ± 0.21 0.659
Proteinuria positive/total (%) 0/8 (0%) 0/17 (0%) NA
ANA positive/total (%) 8/8 (100%) 17/17 (100%) NA
Antids DNA antibodies positive/total (%) 1/8 (12.5%) 3/17 (17.6%) 0.743
Anticardiolipin antibodies positive/total (%) 2/8 (25%) 3/17 (17.6%) 0.668
SLEDAI: Systemic Lupus Erythematosus Disease Activity Index, SLICC: Systemic Lupus International Collaborating Clinics, ANA: anti-
nuclear antibodies, Anti-dsDNA: anti-double stranded DNA, n: number, NA: not applicable.
* Highly signiﬁcant (p< 0.001).
** Signiﬁcant (p< 0.05).
Table 3 Comparison between microchimeric renal and cutaneous lupus women regarding clinical variables and reproductive history.
Variables Microchimeric renal (n= 25) Microchimeric cutaneous (n= 8) p Value
Number of pregnancies 3.8 ± 1.1 1.0 ± 0.0 0.000*
Number of live birth sons 1.3 ± 1.4 0.37 ± 0.51 0.080
Number of abortions 1.9 ± 1.4 0.62 ± 0.51 0.000*
Age of oldest son (years) 18.6 ± 3.5 4.3 ± 0.57 0.000*
SLEDAI 15.9 ± 2.8 3.6 ± 0.37 0.000*
SLICC damage index 6.1 ± 0.86 1.9 ± 0.73 0.000*
SLEDAI: Systemic Lupus Erythematosus Disease Activity Index, SLICC: Systemic Lupus International Collaborating Clinics, n: number.
* Highly signiﬁcant (p< 0.001).
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among those with live birth sons, abortions and two women
with daughters.
Within the lupus nephritis group, 12 patients were mothers
to at least one live birth son, 10 women gave history of at least
one abortion. Ten patients gave birth to at least one daughter
and three females did not report any pregnancy. All females
with live birth sons, abortions and three patients out of 10 with
daughters were microchimeric.Regarding cutaneous lupus group, three patients had at
least one live birth son, while ﬁve women reported at least
one abortion, eight patients had given birth to at least one
daughter and nine females reported no history of pregnancy.
All women who gave history of having live birth sons and
abortions were microchimeric. Moreover those with daughters
or gave no history of pregnancy were not microchimeric.
Microchimerism was signiﬁcantly associated with increased
number of pregnancies among the renal lupus group (Table 1).
Y chromosome microchimerism in patients with systemic lupus erythematosus 31Meanwhile, this association could not be detected in the
cutaneous lupus group (Table 2). In addition, a signiﬁcant in-
crease in the number of pregnancies, abortions and age of the
oldest son were detected on investigating microchimeric wo-
men with renal lupus against microchimeric cutaneous lupus
females. Furthermore the difference between both groups
regarding the number of live birth sons had approached statis-
tical signiﬁcance (Table 3).
The mean number of pregnancies, live birth sons, abortions
and age of the oldest son were signiﬁcantly higher, t= 7.2
(p< 0.001), t= 2.04 (p< 0.05), t= 2.8 (p< 0.05), t= 6.2
(p< 0.001), respectively, among microchimeric renal lupus
patients than those of microchimeric control subjects and were
not signiﬁcant regarding the cutaneous lupus group when com-
pared to microchimeric healthy females except for the age of
the oldest son t= 3.2 (p< 0.05) .4. Discussion
SLE is an immune mediated disease that affects several organs
and has a variety of clinical symptoms. It is characterized by
the presence of autoantibodies particularly against nuclear
components [16]. Despite extensive research, the etiology of
SLE is still unknown but is probably multifactorial. SLE oc-
curs in women and men at a ratio of approximately 10:1. In
women, the ﬁrst symptoms most often occur during their fer-
tile years [17]. This is interesting in terms of whether micro-
chimerism plays a role in SLE, because pregnancy is thought
to be the most likely source of microchimeric cells [18].
This study had detected a signiﬁcant increase in Y chromo-
some microchimerism frequency among SLE patients com-
pared to healthy control subjects. A ﬁnding which is
supported by other authors who reported that microchimerism
occurs more often in SLE patients than healthy controls [19,20].
Kremer Hovinga et al. [18] noted that they could not exclude
the possibility that microchimeric cells are immunological cells
which under certain circumstances may become targets of a cer-
tain immune response leading to the development of SLE. On
the contrary, a former study revealed that no Y chromosome
speciﬁc DNA could be detected in any of patients with SLE
[21]. Our results showed a statistically signiﬁcant higher per-
centage of microchimerism in women with renal lupus than
those with cutaneous lupus. In the literature, there were no
studies comparing the frequency of microchimerism in renal lu-
pus with cutaneous lupus patients but a higher mean number of
male equivalent cells were found in patients with renal lupus
than patients with no renal involvement [22].
Several studies had stated that age, serum creatinine and pro-
teinuria were not predictors for the presence of microchimerism
among females with lupus nephritis [20,23], which was true for
patients with cutaneous lupus and contradictory to our ﬁndings
in lupus nephritis women.Mosca et al. [22] reported the absence
of statistically signiﬁcant relation between the presence of
microchimerism and disease activity measured by European
Consensus Lupus ActivityMeasurement (ECLAM), they noted
that their SLE patients had low level of disease activity. On the
other hand, a relationship was recognized between inﬂamma-
tion and microchimerism, which resulted in a conclusion that
microchimeric cellsmay be associatedwith the pathological pro-
cess in SLE [24]; this could explain the signiﬁcant association be-
tween microchimerism and disease activity measured bySLEDAI in renal lupus group and the signiﬁcant increase in
themean of SLEDAI score inmicrochimeric renal lupus females
than those with cutaneous lupus.
Microchimeric male cells were not found in cutaneous le-
sions of patients with SLE [25]. But an autopsy study had
pointed to a relationship between the presence of microchimer-
ism and organ injury which was more evident in kidneys, lungs
and hearts of SLE patients [18]. This may be a clue for the high
signiﬁcant increase in SLICC damage index among microchi-
meric patients with renal lupus when compared to females with
cutaneous lupus. To our knowledge there were no previous re-
ports that had investigated the connection between microchim-
erism and SLICC disease damage index, a former study had
mentioned that patients with cutaneous lupus do not cross
the threshold of disease severity that causes tissue damage, it
also suggested that extensive maternal tissue damage may be
required for the development of microchimerism in SLE [25].
Because pregnancy is very common and autoimmune dis-
eases are rare, it is likely that only certain subsets of microchi-
meric cells have pathogenic potential. In women who had been
pregnant several times, a heterogenous population of fetal mic-
rochimeric cells was recognized [26,27]. Our work and Kremer
Hovinga et al. [23] have detected that microchimeric women
with lupus nephritis had experienced signiﬁcantly more num-
ber of pregnancies than patients without microchimerism.
Moreover, this relation between number of pregnancies and
microchimerism was not signiﬁcant regarding cutaneous lupus
group. In addition, the microchimeric renal lupus females
showed signiﬁcantly higher mean number of pregnancies than
the cutaneous lupus patients as well as microchimeric healthy
women.
The number of Y chromosome positive cells was not signif-
icantly different in SLE women who gave birth to one son ver-
sus more than one son [28]. Similarly, another study had
observed that there is no clear cut relationship between num-
ber of live birth boys and the presence of Y chromosome
microchimerism in patients with lupus nephritis for which a
possible reason is that not every former pregnancy may lead
to persistence of microchimeric cells and if do persist, their
number may differ per pregnancy [23]. For instance, in this
study microchimeric renal lupus females showed an increase
in the number of live birth sons which was signiﬁcant versus
healthy controls and had approached signiﬁcance when com-
pared to microchimeric cutaneous lupus women. This may
be explained by the highest mean number of pregnancies for
microchimeric renal lupus patients versus microchimeric cuta-
neous lupus females or healthy controls which increases the
possibility for occurrence of microchimerism.
Since it has been demonstrated that termination of preg-
nancy signiﬁcantly increases fetomaternal cell trafﬁcking, com-
plications of pregnancy were considered to be possible
inﬂuential factors on the persistence of microchimeric cells.
The only complication that could be reliably found in selected
studies was a history of fetal loss [29]. This may clarify the sig-
niﬁcant increase in the number of abortions among our lupus
nephritis patients against microchimeric healthy control sub-
jects and microchimeric women with cutaneous lupus. It was
postulated that miscarriages and induced abortions had re-
sulted in an increased number of microchimeric cells compared
to normal pregnancies, both increased transfer and a high pro-
liferative capacity are potential explanations for better engraft-
ment and/or maintenance of fetal microchimerism after
32 O. Abdulaziez et al.abortion [26,30]. It has also been assumed that a previous
spontaneous abortion with unrecognized male fetus could re-
sult in persistence of male DNA [29].
Several studies have reported the presence of microchimeric
cells in the peripheral blood and tissues of healthy women long
after pregnancy [31,32]. Apparently some fetal cells escape
elimination by the immune system and survive in the maternal
circulation of healthy women for many years after delivery.
However reports have appeared to implicate microchimerism
as the cause of immune mediated diseases [33]. Previously, a
signiﬁcant relation was found between the age of the oldest
son and microchimerism in patients with renal lupus and it
had also been noted that the highest numbers of fetal DNA
copies were found among SLE women having the oldest son
[19,23]. During this study, we have discovered that the mean
age of oldest sons who were born to microchimeric females
with renal and cutaneous lupus was signiﬁcantly higher than
among those who were born to microchimeric healthy women.
Indeed, the tendency of having increased number of Y chro-
mosome microchimeric cells in those women with older sons
gives support to the idea that it took sometime for fetal cells
to repopulate and establish a cell line [29]. However, this
may result in the activation of microchimeric cells later in life
and lead to establishment of an autoimmune disease [34].
Interestingly, we have found Y chromosome microchimer-
ism in three females with lupus nephritis and two healthy con-
trol subjects who had only daughters and gave no history of
son delivery or abortions. One potential explanation for this
could be a non recognized male miscarriage. [35]. A second
possibility is from a vanished male twin [36].
This work had investigated Y chromosome microchimerism
in renal versus cutaneous lupus patients. Indeed, we have not
found during research other articles discussing this point ex-
cept one autopsy study on a limited number of SLE patients
(seven patients) which had detected male cells in kidneys and
skin biopsies of six and two patients, respectively [18]. The
main factors which had been suggested to potentiate the role
of fetal microchimerism in SLE such as disease activity, disease
damage, number of pregnancies, abortions and age of oldest
sons were found to be of statistical signiﬁcant effect on screen-
ing microchimeric renal lupus females against cutaneous lupus
patients with fetal microchimerism which may be claimed to be
the cause of increased frequency of Y chromosome microchim-
erism among renal than cutaneous lupus women.
The study provides a preliminary possibility that microchi-
meric cells may have a pathogenic signiﬁcance in SLE. The
presence of fetal microchimerism in healthy control subjects
suggests that additional genetic or environmental factors
may be required to trigger disease. We have detected a relation
between microchimerism and pregnancy history as well as clin-
ical disease parameters; more evident in renal than cutaneous
lupus females which was most probably due to the high inﬂam-
matory and destructive nature of renal lupus disease. Further
studies are needed to fully understand the role of this phenom-
enon in SLE patients with different clinical entities, as this is a
promising ﬁeld of investigation which may lead to novel strat-
egies in treatment.
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